Acquisition of Fulvestrant 250 mg/5 ml Injection Solution - CPA 961/2024
This tender has been awarded
Awarded to ALLOGA PORTUGAL - ARMAZENAGEM E DISTRIBUIÇÃO FARMACÊUTICA, LDA
About This Opportunity
TranslatedThis tender pertains to the acquisition of Fulvestrant 250 mg/5 ml injection solution, specifically designed for intramuscular administration. The procurement is identified by the reference CPA 961/2024. Fulvestrant is a medication used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. The tender is aimed at suppliers who can provide this pharmaceutical product in the specified dosage and form. Key requirements may include compliance with regulatory standards for pharmaceutical products, quality assurance certifications, and the ability to deliver the product within stipulated timelines. The location for the delivery and the intended use of the medication will likely be within healthcare facilities that cater to oncology patients. Interested bidders should ensure they meet all necessary qualifications and are prepared to submit detailed proposals that outline their capability to fulfill the contract requirements. This procurement is crucial for maintaining the supply of essential medications in the healthcare system, thereby supporting ongoing treatment programs for patients in need.
This is a supplies contract in the health and medical services, education and training and trade and industry sectors, with a focus on Pharmaceuticals, Manufacturing and Quality Standards. Located in Portugal, Europe, this opportunity is open to firms and consortiums, with an estimated budget of EUR 2,320.
Published through base_gov_pt, a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.
Description
Original language: PortugueseThis tender notice pertains to the procurement of Fulvestrant 250 mg/5 ml injectable solution, designated as CPA 961/2024, in Portugal. The contracting authority is seeking qualified suppliers to provide this pharmaceutical product, which is primarily utilized for the treatment of hormone receptor-positive breast cancer in postmenopausal women. The procurement is part of the broader effort to ensure the availability of essential medications in the healthcare system, thereby improving patient outcomes in oncology.
Participants in this tender are expected to demonstrate compliance with stringent regulatory standards and quality assurance measures applicable to pharmaceutical products. Typical requirements for this type of procurement may include the provision of detailed technical specifications, evidence of Good Manufacturing Practices (GMP) certification, and documentation showcasing the product’s efficacy and safety. Suppliers must also be prepared to meet delivery timelines and logistical requirements, ensuring that the product is supplied in accordance with the stipulated conditions.
Additionally, bidders may need to present their pricing structure, including any volume discounts, and provide information on after-sales support and potential training for healthcare professionals. Given the importance of timely and reliable access to cancer medications, the tender underscores the commitment of the Portuguese health authorities to procure high-quality pharmaceuticals while fostering competitive procurement practices in the public sector. Potential bidders are encouraged to monitor the Portal BASE for further details and updates regarding submission deadlines and specific application procedures.
Data provenance
This notice is sourced from base_gov_pt and was originally published on February 10, 2026. Last refreshed 10 days ago. Original language: Portuguese. BidsFactory mirrors official procurement notices and links back to the source for full legal text.
About Unidade Local de Saúde do Alto Minho, EPE (ULSAM)
Unidade Local de Saúde do Alto Minho, EPE (ULSAM) has issued 512 procurement notices on BidsFactory, including 0 currently open and 462 awarded contracts. Activity concentrates in General Supplies & Services, Health & Medical, and Information & Communication Technology. All notices are published for Portugal. Notices are distributed via base_gov_pt. Most recent publication: June 18, 2026.
Frequently asked questions about this tender
How can I submit a bid?
Visit base_gov_pt to access the full notice, required documents, and submission instructions provided by the contracting authority.
Is this tender still open?
No — the contract has already been awarded to ALLOGA PORTUGAL - ARMAZENAGEM E DISTRIBUIÇÃO FARMACÊUTICA, LDA. The award notice is archived on BidsFactory for transparency and market intelligence.
Who is the contracting authority?
This notice was issued by Unidade Local de Saúde do Alto Minho, EPE (ULSAM) in Portugal. The authority is responsible for evaluating bids, awarding the contract, and managing performance.
What type of contract is this?
This is a Supplies contract in the Health & Medical sector. The classification helps bidders match the opportunity to their qualifications and registered scope of supply.
What is the estimated budget?
The estimated contract value is Up to €2,320. Bidders should ensure their proposals are consistent with this range and account for any local taxes and contract execution costs.
Where will the contract be performed?
The contract is for delivery in Portugal. Foreign bidders should review local registration, taxation, and any in-country presence requirements before submitting.
Find tenders like this automatically
Set up alerts and filters that match your business — never miss a relevant opportunity again.